In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study

Parkinsonism and Related Disorders

Volumn 16, Issue 6, 2010, Pages 404-408

  Miyoshi, Michie ^a   Shinotoh, Hitoshi ^a   Wszolek, Zbigniew K ^b   Strongosky, Audrey J ^b   Shimada, Hitoshi ^a   Arakawa, Ryosuke ^a   Higuchi, Makoto ^a   Ikoma, Yoko ^a   Yasuno, Fumihiko ^a   Fukushi, Kiyoshi ^a   Irie, Toshiaki ^a   Ito, Hiroshi ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Acetylcholine; Dopamine; FTDP 17; Magnetic resonance imaging; Microglia; Positron emission tomography

Indexed keywords

ACETYLCHOLINESTERASE; DAA 1106 C 11; DOPAMINE; LEVODOPA; LEVODOPA C 11; MAPT PROTEIN; N METHYLPIPERIDIN 4 YL ACETATE C 11; PROTEIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN ATROPHY; CASE REPORT; CELL ACTIVATION; CHROMOSOME 17; CINGULATE GYRUS; CONTROLLED STUDY; DOPAMINE METABOLISM; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; MALE; MICROGLIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

ADULT; BRAIN; FRONTOTEMPORAL DEMENTIA; HETEROZYGOTE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MUTATION; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 77953614566     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.04.004     Document Type: Article

References (30)

1. Wszolek Z.K., Tsuboi Y., Ghetti B., Pickering-Brown S., Baba Y., Cheshire W.P. Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet J Rare Dis 2006, 1:30.
2. Cheshire W.P., Tsuboi Y., Wszolek Z.K. Physiologic assessment of autonomic dysfunction in pallidopontonigral degeneration with N279K mutation in the tau gene on chromosome 17. Auton Neurosci 2002, 102:71-77.
3. Ferman T.J., McRae C.A., Arvanitakis Z., Tsuboi Y., Vo A., Wszolek Z.K. Early and pre-symptomatic neuropsychological dysfunction in the PPND family with the N279K tau mutation. Parkinsonism Relat Disord 2003, 9:265-270.
4. Arvanitakis Z., Witte R.J., Dickson D.W., Tsuboi Y., Uitti R.J., Slowinski J., et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord 2007, 13:230-239.
5. Slowinski J., Dominik J., Uitti R.J., Ahmed Z., Dickson D.D., Wszolek Z.K. Frontotemporal dementia and Parkinsonism linked to chromosome 17 with the N279K tau mutation. Neuropathology 2007, 27:73-80.
6. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
7. Neuron 2007, 54:343-344. Erratum in.
8. Yamada T., McGeer E.G., Schelper R.L., Wszolek Z.K., McGeer P.L., Pfeiffer R.F., et al. Histological and biochemical pathology in a family with autosomal dominant parkinsonism and dementia. Neurol Psych Brain Res 1993, 2:26-35.
9. Doorduin J., de Vries E.F., Dierckx R.A., Klein H.C. PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr Pharm Des 2008, 14:3297-3315.
10. 11C]DAA1106. Biol Psychiatry 2008, 64:835-841.
11. Kishore A., Wszolek Z.K., Snow B.J., de la Fuente-Fernandez R., Arwert F., Wijker M., et al. Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family. Neurology 1996, 47:1588-1590.
12. Hirano S., Shinotoh H., Kobayashi T., Tsuboi Y., Wszolek Z.K., Aotsuka A., et al. Brain acetylcholinesterase activity in FTDP-17 studied by PET. Neurology 2006, 66:1276-1277.
13. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993, 4:2412-2414.
14. Folstein M.F., Folstein S.E., McHugh P.R. " Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
15. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000, 55:1621-1626.
16. Beck A.T., Steer R.A., Ball R., Ranieri W.F. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996, 67:588-597.
17. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
18. Fahn S., Marsden C.D., Calne D., Goldstein M. Unified Parkinson's disease, version 3.0. Recent developments in Parkinson's disease 1987, 293-304. Macmillan Healthcare Inofrmation, Florham Park, NJ. S. Fahn, C.D. Marsden, D. Calne, M. Goldstein (Eds.).
19. 11C]DAA1106. J Cereb Blood Flow Metab 2007, 27:173-184.
20. 11C]dopa. Nucl Med Commun 2006, 27:723-731.
21. Mozley P.D., Stubbs J.B., Kim H.J., McElgin W., Kung M.P., Meegalla S., et al. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med 1996, 37:151-159.
22. Shinotoh H., Namba H., Yamaguchi M., Fukushi K., Nagatsuka S., Iyo M., et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999, 46:62-69.
23. Cagnin A., Kassiou M., Meikle S.R., Banati R.B. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics 2007, 4:443-452.
24. Cagnin A., Rossor M., Sampson E.L., MacKinnon T., Banati R.B. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol 2004, 56:894-897.
25. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., et al. Microglial activation in presymptomatic Huntington's disease gene carrier. Brain 2007, 130:1759-1766.
26. Venneti S., Wang G., Nguyen J., Wiley C.A. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol 2008, 67:1001-1010.
27. Ji B., Maeda J., Sawada M., Ono M., Okauchi T., Inaji M., et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 2008, 28:12255-12267.
28. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006, 21:404-412.
29. Pal P.K., Wszolek Z.K., Kishore A., de la Fuente-Fernandez R., Sossi V., Uitti R.J., et al. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinsonism Relat Disord 2001, 7:81-88.
30. Yamada T., McGeer P.L., McGeer E.G. Some immunohistochemical features of argyrophilic grain dementia with normal cortical choline acetyltransferase levels but extensive subcortical pathology and markedly reduced dopamine. J Geriatr Psychiatry Neurol 1992, 5:3-13.